<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8813" href="/d/html/8813.html" rel="external">see "Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Drug information"</a> and <a class="drug drug_patient" data-topicid="10818" href="/d/html/10818.html" rel="external">see "Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F4090481"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cyanokit</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867140"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cyanokit;</li>
<li>Hydro Cobex [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1059323"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote, Cyanide</span>;</li>
<li>
<span class="list-set-name">Nutritional Supplement</span>;</li>
<li>
<span class="list-set-name">Vitamin, Water Soluble</span></li></ul></div>
<div class="block don drugH1Div" id="F53462472"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0b13d122-239a-4137-a700-560aff8a04ca">Cobalamin metabolism disorders</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cobalamin metabolism disorders </b> (eg, cobalamin C disease, transcobalamin C deficiency): Very limited data available, dosage varies depending on clinical condition; optimal dose not established.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Usual initial dose: IM: 1,000 <b>mcg</b>/dose; frequency varies based on clinical condition and vitamin/metabolic parameters; consultation with metabolic specialist is advised. Case reports have described dosing as frequently as daily, three times weekly, or once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25205257','lexi-content-ref-24942828','lexi-content-ref-27905001','lexi-content-ref-11972107','lexi-content-ref-22711730','lexi-content-ref-23301732','lexi-content-ref-24305960']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25205257','lexi-content-ref-24942828','lexi-content-ref-27905001','lexi-content-ref-11972107','lexi-content-ref-22711730','lexi-content-ref-23301732','lexi-content-ref-24305960'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F180754"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Verify dosing units due to large difference in dose for different indications; dosage may be presented in mg or <b>mcg</b>.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0b13d122-239a-4137-a700-560aff8a04ca">Cobalamin metabolism disorders</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cobalamin metabolism disorders </b>(eg, cobalamin C disease, transcobalamin C deficiency): Very limited data available, optimal dose not established.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Usual initial dose: IM: 1,000 <b>mcg</b>/dose; higher doses have been reported and tailored to individual clinical and biochemical response. Frequency varies based on clinical condition and vitamin/metabolic parameters; consultation with metabolic specialist is advised. Case reports have described dosing frequency ranging from daily, three times weekly, or once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25205257','lexi-content-ref-24942828','lexi-content-ref-27905001','lexi-content-ref-11972107','lexi-content-ref-22711730','lexi-content-ref-23301732','lexi-content-ref-24305960']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25205257','lexi-content-ref-24942828','lexi-content-ref-27905001','lexi-content-ref-11972107','lexi-content-ref-22711730','lexi-content-ref-23301732','lexi-content-ref-24305960'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5d45c167-1cac-4768-9b58-6250793d8421">Cyanide poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cyanide poisoning (Cyanokit): </b>Limited data available: <b>Note</b>: If cyanide poisoning is suspected, antidotal therapy must be initiated immediately.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV/Intraosseous: 70 mg/kg as a single infusion; maximum dose: 5,000 mg/dose; may repeat a second dose of 70 mg/kg (maximum dose: 5,000 mg/dose) depending on the severity of poisoning and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24196100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24196100'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b719c3a8-a47b-4ec2-9e29-c4be331c41e5">Pernicious anemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pernicious anemia:</b>
<b>Note: </b>Concurrent folic acid supplementation may also be needed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild to moderate: </i>Infants, Children, and Adolescents: IM: Initial: 100 <b>mcg</b> daily for ≥2 weeks to target total dose range: 1,000 to 5,000 <b>mcg</b>; maintenance: 30 to 50 <b>mcg</b> monthly.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe, complicated (eg, neurologic involvement):</i> Multiple regimens reported, optimal dose not established: Infants, Children, and Adolescents: IM: Initial: 1,000 <b>mcg</b> daily for 7 days or every other day for 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24942828','lexi-content-ref-25953825','lexi-content-ref-Orkin.1','lexi-content-ref-3604755','lexi-content-ref-23301732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24942828','lexi-content-ref-25953825','lexi-content-ref-Orkin.1','lexi-content-ref-3604755','lexi-content-ref-23301732'])">Ref</a></span>); some experts suggest treatment until clinical improvement of neurologic symptoms observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24942828']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24942828'])">Ref</a></span>); then follow with maintenance: 1,000 <b>mcg</b> every 2 to 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24942828','lexi-content-ref-23301732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24942828','lexi-content-ref-23301732'])">Ref</a></span>). For infants and young children, some experts have recommended doses as low as 50 to 100 <b>mcg</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Orkin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Orkin.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8e409a20-06c4-484c-958f-b88e7750f0aa">Vitamin B<sub>12</sub> deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vitamin B<sub>12</sub> deficiency:</b> Limited data available; dosing regimens variable:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dietary deficiency: </i>Infants (breastfed with vitamin B<sub>12</sub> deficient mothers): Infants ≥6 weeks: IM: 400 <b>mcg</b> once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18595990','lexi-content-ref-20508991','lexi-content-ref-26678525']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18595990','lexi-content-ref-20508991','lexi-content-ref-26678525'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Malabsorption: </i>Infants, Children, and Adolescents: IM: 250 to 1,000 <b>mcg</b> daily or every other day for 1 week, then weekly for 4 to 8 weeks, and then monthly for life; younger children should receive monthly doses of 100 <b>mcg </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20508991','lexi-content-ref-Sachdev.1','lexi-content-ref-23301732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20508991','lexi-content-ref-Sachdev.1','lexi-content-ref-23301732'])">Ref</a></span>). For infants and young children, some experts have recommended doses as low as 50 to 100 <b>mcg</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Orkin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Orkin.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51113359"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51113360"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F180735"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8813" href="/d/html/8813.html" rel="external">see "Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5d45c167-1cac-4768-9b58-6250793d8421">Cyanide poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cyanide poisoning:</b>
<b>Note:</b> If cyanide poisoning is suspected, antidotal therapy must be given immediately. Preferred in fire victims who present with both cyanide and carbon monoxide poisoning.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV/IO:</b> Initial: 5 <b>g</b> as single infusion over 15 minutes; may repeat a second 5 <b>g</b> dose over 15 minutes to 2 hours (total dose: 10 <b>g</b>) depending on the severity of poisoning and clinical response.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea19fb67-b752-4bfa-a6d6-b5afc1868aec">Hydrogen sulfide poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hydrogen sulfide poisoning (off-label use): Note:</b> May be beneficial if given immediately following exposure to hydrogen sulfide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21396232','lexi-content-ref-25546714','lexi-content-ref-17976885']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21396232','lexi-content-ref-25546714','lexi-content-ref-17976885'])">Ref</a></span>); use has not been validated in clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Holstege.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Holstege.1'])">Ref</a></span>). The dosing regimen used to treat cyanide poisoning should be utilized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.1'])">Ref</a></span>). Consultation with a clinical toxicologist or poison control center is highly recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV/IO:</b> Initial: 5 <b>g</b> over 15 minutes; may repeat a second 5 <b>g</b> dose depending on the severity of poisoning and clinical response. Maximum cumulative dose: 10 <b>g </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Holstege.1','lexi-content-ref-Expert.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Holstege.1','lexi-content-ref-Expert.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c07913cf-1aa8-4a3b-b133-c994f8db4e4a">Vasoplegic syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasoplegic syndrome (off-label use): Note:</b> Consider in patients who are refractory to methylene blue or as an alternative to methylene blue in patients who are at risk of serotonin syndrome or have glucose-6-phosphate dehydrogenase deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30598380']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30598380'])">Ref</a></span>). Dosing is not standardized; refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 5 to 10 <b>g</b> over 10 to 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29573551','lexi-content-ref-28994688','lexi-content-ref-30598380','lexi-content-ref-24792267','lexi-content-ref-29209927']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29573551','lexi-content-ref-28994688','lexi-content-ref-30598380','lexi-content-ref-24792267','lexi-content-ref-29209927'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Initial: IV bolus 125 to 250 <b>mg</b>, followed by continuous IV infusion rate of 250 to 500 <b>mg</b>/h (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28012726','lexi-content-ref-27749291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28012726','lexi-content-ref-27749291'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="80ec2868-dab9-4252-8112-3c95cfa22874">Vitamin B<sub>12</sub> deficiency, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vitamin B<sub>12</sub> deficiency, treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Folic acid supplementation may also be required. Oral vitamin B<sub>12</sub> (eg, cyanocobalamin) may be used for less severe deficiency and/or maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24942828']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24942828'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Severe/symptomatic anemia or neurologic/neuropsychiatric findings:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial therapy:</i>
<b>IM:</b> 1,000 mcg every other day or once daily for 1 to 2 weeks, then 1,000 mcg once weekly for 4 to 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24942828','lexi-content-ref-31917200','lexi-content-ref-23301732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24942828','lexi-content-ref-31917200','lexi-content-ref-23301732'])">Ref</a></span>). Alternatively, if neurologic symptoms are present, may initiate 1,000 mcg every other day for up to 3 weeks or until no further improvement in signs or symptoms, then switch to 1,000 mcg once weekly for up to 12 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24942828','lexi-content-ref-Means.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24942828','lexi-content-ref-Means.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance therapy:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Continue parenteral therapy until the deficiency has been corrected and signs and symptoms have resolved before switching to oral therapy (cyanocobalamin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Means.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Means.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IM:</b> 1,000 mcg every 3 months; in patients with neurologic or neuropsychiatric symptoms, administer 1,000 mcg every 2 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24942828']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24942828'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Mild symptoms or asymptomatic: IM:</b> 1,000 mcg once weekly for 4 weeks; maintenance dose: 1,000 mcg once every 2 to 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24942828','lexi-content-ref-Means.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24942828','lexi-content-ref-Means.2021'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Duration of therapy:</b> Continue indefinitely in patients with pernicious anemia or other irreversible cause of deficiency (eg, bariatric surgery); may discontinue therapy if a reversible cause of deficiency (eg, reduced dietary intake) has been addressed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28925645','lexi-content-ref-23301732','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28925645','lexi-content-ref-23301732','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
<div class="block dora drugH1Div" id="F50991859"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989155"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F180717"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM injection:</b> Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Pruritus, skin rash (transient)</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Diarrhea (mild, transient)</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Pain at injection site</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Swelling (feeling of swelling of the entire body)</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>IV infusion:</b></p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased blood pressure (18% to 28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (6% to 33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema (94% to 100%; may last up to 2 weeks), skin rash (20% to 44%; predominantly acneiform eruption; can appear 7 to 28 days after administration and usually resolves within a few weeks)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (6% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urine discoloration (100%; may last up to 5 weeks after administration), calcium oxalate nephrolithiasis (56% to 61%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphocytopenia (8% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion site reaction (6% to 39%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort, peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness, memory impairment, restlessness</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; Metabolic: Hot flash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, diarrhea, dyspepsia, dysphagia, hematochezia, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye irritation, eye redness, swelling of eye</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dry throat, dyspnea, pharyngeal edema</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Acute renal failure, acute tubular necrosis, angioedema, calcium oxalate nephrolithiasis (Legrand 2016), methemoglobinemia (Jiwani 2017), renal insufficiency</p></div>
<div class="block coi drugH1Div" id="F180728"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">IM: Hypersensitivity to hydroxocobalamin or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">IV (Cyanokit): There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F180714"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: According to the manufacturer, treatment of severe vitamin B<sub>12</sub> megaloblastic anemia may result in severe hypokalemia, sometimes fatal, due to intracellular potassium shift upon anemia resolution; however, in more recent experience, while some patients may experience hypokalemia with initial treatment, it is transient and unlikely to be clinically significant (Carmel 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertension: Cyanide poisoning: Increased BP (≥180 mm Hg systolic or ≥110 mm Hg diastolic) may occur with infusion; elevations usually noted at the beginning of the infusion, peak toward the end of the infusion, and return to baseline within 4 hours following the end of the infusion. May offset hypotension induced by nitrite administration or cyanide; monitor BP during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: May cause photosensitivity; avoid direct sunlight while skin remains discolored.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal injury: Renal injury, requiring hemodialysis for recovery in some cases, has been reported and may include acute renal failure with acute tubular necrosis, renal impairment, and urine calcium oxalate crystals; monitor renal function for ≥7 days following therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombocytosis: Treatment of severe vitamin B<sub>12</sub> megaloblastic anemia may result in thrombocytosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Megaloblastic anemia: May mask previously unrecognized folate deficiency; vitamin B<sub>12</sub> is not a substitute for folic acid.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polycythemia vera: Vitamin B<sub>12</sub> deficiency masks signs of polycythemia vera; vitamin B<sub>12</sub> administration may unmask this condition.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fire victims: Hydroxocobalamin can discolor the skin and exudates, complicating the assessment of burn severity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cyanokit: Use caution or consider alternatives in patients known to be allergic to, or who have experienced anaphylaxis with hydroxocobalamin or cyanocobalamin. Collection of pretreatment blood cyanide concentrations does not preclude administration and should not delay administration in the emergency management of suspected or confirmed cyanide toxicity. Only pretreatment cyanide concentrations may be useful since postinfusion concentrations may be inaccurate. Treatment of cyanide poisoning should include external decontamination and supportive therapy. Use caution with concurrent use of other cyanide antidotes; safety has not been established. Consider consultation with a poison control center at 1-800-222-1222.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hemodialysis: Hydroxocobalamin may interfere with and/or trip alarms in patients who use hemodialysis machines that rely on colorimetric technology.</p></div>
<div class="block foc drugH1Div" id="F180723"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1000 mcg/mL (30 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cyanokit: 5 g (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cyanokit: 5 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F180710"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16323186"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Hydroxocobalamin Acetate Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mcg/mL (per mL): $1.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Cyanokit Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 g (per each): $1,162.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867141"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1000 mcg/mL ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cyanokit: 5 g (1 ea)</p></div>
<div class="block adip drugH1Div" id="F53567167"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Cyanocobalamin is preferred over hydroxocobalamin as a treatment agent for anemia due to reports of antibody formation to the hydroxocobalamin-transcobalamin complex. Cyanide is a clear colorless gas or liquid with a faint bitter almond odor. Cyanide reacts with trivalent ions in cytochrome oxidase in the mitochondria leading to histotoxic hypoxia and lactic acidosis. Signs and symptoms of cyanide toxicity include headache, altered mental status, dyspnea, mydriasis, chest tightness, nausea, vomiting, tachycardia/hypertension (initially), bradycardia/hypotension (later), seizures, cardiovascular collapse, or coma. Guidelines suggest that at least 10 <b>g</b> be stocked. This is enough to treat one patient weighing 100 kg for an initial 8- to 24-hour period (Dart 2009). If several victims, consider initiating with half-dose of hydroxocobalamin up to 5,000 mg/dose (Mintegi 2013).</p></div>
<div class="block admp drugH1Div" id="F52613004"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Administer 1,000 <b>mcg</b>/mL injection IM only; do not administer SubQ</p>
<p style="text-indent:-2em;margin-left:2em;">IV/Intraosseous (Cyanokit): Administer IV using vented tubing. Administer as IV infusion over 15 minutes; if second dose is needed, administer second dose over 15 minutes to 2 hours depending upon the patient's clinical state; intraosseous may be used in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24196100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24196100'])">Ref</a></span>). Hydroxocobalamin is chemically incompatible with sodium thiosulfate and sodium nitrite; separate IV lines must be used if concomitant administration is desired. Use of intraosseous administration has been reported in adult patients in whom IV administration is not possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33692053']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33692053'])">Ref</a></span>); animal studies also support intraosseous administration as a viable alternative route of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25377396','lexi-content-ref-28644688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25377396','lexi-content-ref-28644688'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F180726"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Administer 1,000 mcg/mL solution by IM injection only.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV/</b>
<b>Intraosseous:</b> Cyanokit: Administer IV using vented tubing. Hydroxocobalamin is chemically incompatible with sodium thiosulfate and sodium nitrite and separate IV lines must be used if concomitant administration is desired<b> (the safety and efficacy of coadministration are not established)</b>. Use of intraosseous administration has been reported in patients in whom IV administration is not possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33692053']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33692053'])">Ref</a></span>); animal studies also support intraosseous administration as a viable alternative route of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25377396','lexi-content-ref-28644688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25377396','lexi-content-ref-28644688'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F180732"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Solution for IM injection: Store at 20°C to 25°C (68°F to 77°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">IV infusion (Cyanokit): Prior to reconstitution, store at 25°C (77°F): excursions permitted to 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:4em;">Temperature variation exposure allowed for transport of lyophilized form:</p>
<p style="text-indent:-2em;margin-left:6em;">Usual transport: ≤15 days at 5°C to 40°C (41°F to 104°F)</p>
<p style="text-indent:-2em;margin-left:6em;">Desert transport: ≤4 days at 5°C to 60°C (41°F to 140°F)</p>
<p style="text-indent:-2em;margin-left:6em;">Freezing/defrosting cycles: ≤15 days at -20°C to 40°C (-4°F to 104°F)</p>
<p style="text-indent:-2em;margin-left:4em;">Following reconstitution, store up to 6 hours at ≤40°C (104°F); do not freeze. Discard any remaining solution after 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pharmacy supply of emergency antidotes:</i> Guidelines suggest that at least 10 g of hydroxocobalamin be stocked, especially in hospitals which serve industrial areas. Suggested amount is stated to be a sufficient quantity to treat 1 patient weighing 100 kg for an initial 8- to 24-hour period (Dart 2018); actual amount to be stocked should take into account site-specific and population-specific needs.</p></div>
<div class="block usep drugH1Div" id="F53567235"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">IM injection: Treatment of pernicious anemia (uncomplicated or accompanied by nervous system involvement); treatment of vitamin B<sub>12</sub> deficiency due to dietary deficiencies, malabsorption diseases, inadequate secretion of intrinsic factor, competition for vitamin B<sub>12</sub> by intestinal parasites/bacteria, or inadequate utilization of B<sub>12</sub> (eg, during neoplastic treatment) (All indications: FDA approved in pediatric patients [age not specified] and adults). Has also been used in patients with metabolic cobalamin disorders.</p>
<p style="text-indent:-2em;margin-left:2em;">IV infusion (Cyanokit): Treatment of cyanide poisoning (known or suspected) (FDA approved in adults).</p></div>
<div class="block cyt drugH1Div" id="F13299483"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F180718"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): May diminish the therapeutic effect of Vitamin B12.<i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F56591837"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Strict vegetarian or vegan diets (eg, without eggs or dairy products) may result in vitamin B<sub>12</sub> deficiency (NIH 2021; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Adequate intake (IOM 1998): </b></p>
<p style="text-indent:-2em;margin-left:4em;">1 to 6 months: 0.4 mcg daily.</p>
<p style="text-indent:-2em;margin-left:4em;">7 to 12 months: 0.5 mcg daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommended intake (IOM 1998): </b></p>
<p style="text-indent:-2em;margin-left:4em;">1 to 3 years: 0.9 mcg daily.</p>
<p style="text-indent:-2em;margin-left:4em;">4 to 8 years: 1.2 mcg daily.</p>
<p style="text-indent:-2em;margin-left:4em;">9 to 13 years: 1.8 mcg daily.</p>
<p style="text-indent:-2em;margin-left:4em;">≥14 years: 2.4 mcg daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Pregnancy: 2.6 mcg daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Lactation: 2.8 mcg daily.</p></div>
<div class="block pri drugH1Div" id="F4010117"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Hydroxocobalamin crosses the placenta (Huemer 2005; Roderique 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Data on the use of hydroxocobalamin in pregnancy for the treatment of cyanide poisoning and cobalamin defects are limited (Brunel-Guitton 2010; Huemer 2005; Roderique 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Cyanide crosses the placenta. Cyanide poisoning can be fatal for the pregnant female and fetus if untreated; treatment should not be withheld due to pregnancy. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant females if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>
<div class="block mopp drugH1Div" id="F53567215"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Baseline: Serum vitamin B<sub>12</sub>, hemoglobin, hematocrit, erythrocyte and reticulocyte count, folate and iron levels; serum methylmalonic acid (MMA) and total homocysteine levels in untreated patients to confirm vitamin B<sub>12</sub> deficiency (and extent of deficiency) (Stabler 2013)</p>
<p style="text-indent:-2em;margin-left:2em;">With treatment: Serum vitamin B<sub>12</sub> and peripheral blood counts should be monitored 1 month after beginning treatment, then every 3 to 6 months thereafter. Evaluate serum MMA and total homocysteine levels periodically to confirm adequate supplementation (Stabler 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Additional indication-specific monitoring:</p>
<p style="text-indent:-2em;margin-left:4em;">Megaloblastic/pernicious anemia: In addition to normal hematological parameters, serum potassium and platelet counts should be monitored during therapy. <b>Note:</b> Some patients may develop hypokalemia during initial treatment; however, this is unlikely to be clinically significant (Carmel 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Cyanide poisoning: Blood pressure and heart rate during and after infusion, serum lactate levels, venous-arterial PO<sub>2</sub>gradient. Pretreatment cyanide levels may be useful as post infusion levels may be inaccurate.</p></div>
<div class="block rerp drugH1Div" id="F53567052"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Serum vitamin B<sub>12</sub> levels: Normal: 200 to 800 pg/mL (Powers 2021).</p></div>
<div class="block pha drugH1Div" id="F180713"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Hydroxocobalamin (vitamin B<sub>12a</sub>) is a precursor to cyanocobalamin (vitamin B<sub>12</sub>). Cyanocobalamin acts as a coenzyme for various metabolic functions, including fat and carbohydrate metabolism and protein synthesis, used in cell replication and hematopoiesis. In the presence of cyanide, each hydroxocobalamin molecule can bind one cyanide ion by displacing it for the hydroxo ligand linked to the trivalent cobalt ion, forming cyanocobalamin, which is then excreted in the urine.</p></div>
<div class="block phk drugH1Div" id="F4010127"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Following IV administration of Cyanokit:</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>:<sub></sub>Free cobalamins-(III): 280.7 to 349.5 L; Total cobalamins-(III): 21.8 to 25.6 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Significant; forms various cobalamin-(III) complexes</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Does not undergo metabolism</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 26 to 31 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (50% to 60% within initial 72 hours)</p></div>
<div class="block phksp drugH1Div" id="F51159790"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Sex: When normalized for body weight, men and women revealed no major pharmacokinetic differences.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539877"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Depovit B12 | Forta b12</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dosixbe</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cyanokit | Erycytol | Hepavit</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cobal-b12 | Cyanokit | Hydroxo B12 | Neo cytamen | Vita b12</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cynomin H</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cyanokit</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cronobe | Rubranova</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cyanokit | Novobedouze | Vitarubin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Hydroxocobalamine hydrochloride</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Decamil-b12</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cyanokit</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cefavit b12 depot | Cyanokit | Lophakomp B12</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Hydroxo</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cohemin | Cyanokit</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cobalamin depot | Depovit B12 | Hydrovit b12</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cyanokit | Megamilbedoce</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cohemin | Cyanokit</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cyanokit | Dodecavit | Hydroxo | Novobedouze</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cobalin h | Cyanokit | Hydroxocobalam | Neo cytamen</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dodecavite | Hydroxocobalamina | Neo cytamen</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cyanokit</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cobalin h | Cyanokit | Neo cytamen</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Neurobion h</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cyanokit | Oh b12</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Vitamin b12</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Anemisol h | Aquo b | B coba | B valet b12 | Bistin | Cobalamin h isei | Colsamine s towa | Dasvit h | Funacomin f | Hicobalamin | Hicobalan | Hydocomin | Hydroxomin | Ohb12 | Redisol h | Runova | Solco h aventis | Solco h tobishi | Takata b12 | Twelvmin s merck hoei | Vigolatin | Vitamilon a12</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Cobalin h</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Forta b12</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Douzabine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cefavit b12 depot | Cyanokit</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Forta b | Novobedouze</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Novobedouze</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Anevit | Axofor | Droxivit 12 | Duradoce | Hidroxocobalamina</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cyanokit</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cyanokit | Vitamin b12 | Vitamin b12 depot orifarm</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cyanokit | Neo cytamen</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cobavit 12 | Hidroxamin-12 | Hidroxocobalam | Hidroxocobalamina | Minedrox</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cobalin h | Cyanokit | Dodecavit</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cyanokit</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cyanokit | Hidroxocobalamina | Ohb 12 | Ohb12</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Depofort B12 | Depovit B12 | Norogrizovim | Vitamin B12 Depot | Vitarubin Depot</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cyanokit | Hydroxocobalamin alternova</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cyanokit</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cyanokit</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bistin | Cobalidrina | Cobamine-oh | Depo B12 | Depovitan B12 | Esesin | Hybramin | Hycomin | Hydroxe-b12 | Hydroxo | Hydroxobam | Hydroxocobalamine | Metroneuril | Ohb12 | Vitamin b12</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Droxofor | Hidroxocobalamina ion</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cozamon | Droxofor | Duradoce | Hidrodoce | Ibedox</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29573551">
<a name="29573551"></a>An SS, Henson CP, Freundlich RE, McEvoy MD. Case report of high-dose hydroxocobalamin in the treatment of vasoplegic syndrome during liver transplantation. <i>Am J Transplant</i>. 2018;18(6):1552-1555. doi:10.1111/ajt.14736<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/29573551/pubmed" id="29573551" target="_blank">29573551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22828651">
<a name="22828651"></a>Anseeuw K, Delvau N, Burillo-Putze G, et al. Cyanide poisoning by fire smoke inhalation: a European expert consensus. <i>Eur J Emerg Med. </i>2013;20(1):2-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/22828651/pubmed" id="22828651" target="_blank">22828651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?" <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.1">
<a name="Expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25205257">
<a name="25205257"></a>Baumgartner MR, Hörster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. <i>Orphanet J Rare Dis</i>. 2014;9:130. doi:10.1186/s13023-014-0130-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/25205257/pubmed" id="25205257" target="_blank">25205257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28472554">
<a name="28472554"></a>Bebarta VS, Garrett N, Brenner M, et al. Efficacy of intravenous cobinamide versus hydroxocobalamin or saline for treatment of severe hydrogen sulfide toxicity in a swine (Sus scrofa) model.<i> Acad Emerg Med</i>. 2017;24(9):1088-1098. doi:10.1111/acem.13213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/28472554/pubmed" id="28472554" target="_blank">28472554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20511644">
<a name="20511644"></a>Bebarta VS, Pitotti RL, Borys DJ, et al. Seven Years of Cyanide Ingestions in the USA: Critically Ill Patients are Common, but Antidote Use is Not. <i>Emerg Med J</i>. 2011;28(2):155-158.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/20511644/pubmed" id="20511644" target="_blank">20511644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25377396">
<a name="25377396"></a>Bebarta VS, Pitotti RL, Boudreau S, Tanen DA. Intraosseous versus intravenous infusion of hydroxocobalamin for the treatment of acute severe cyanide toxicity in a Swine model. <i>Acad Emerg Med</i>. 2014;21(11):1203-1211. doi:10.1111/acem.12518<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/25377396/pubmed" id="25377396" target="_blank">25377396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18595990">
<a name="18595990"></a>Bjørke-Monsen AL, Torsvik I, Saetran H, Markestad T, Ueland PM. Common metabolic profile in infants indicating impaired cobalamin status responds to cobalamin supplementation. <i>Pediatrics</i>. 2008;122(1):83-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/18595990/pubmed" id="18595990" target="_blank">18595990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20508991">
<a name="20508991"></a>Bjørke-Monsen AL, Ueland PM. Cobalamin status in children. <i>J Inherit Metab Dis</i>. 2011;34(1):111-119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/20508991/pubmed" id="20508991" target="_blank">20508991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28012726">
<a name="28012726"></a>Boettcher BT, Woehlck HJ, Reck SE, et al. Treatment of vasoplegic syndrome with intravenous hydroxocobalamin during liver transplantation. <i>J Cardiothorac Vasc Anesth</i>. 2017;31(4):1381-1384. doi:10.1053/j.jvca.2016.10.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/28012726/pubmed" id="28012726" target="_blank">28012726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20830523">
<a name="20830523"></a>Brunel-Guitton C, Costa T, Mitchell GA, Lambert M. Treatment of cobalamin C (cblC) deficiency during pregnancy. <i>J Inherit Metab Dis</i>. 2010;33(suppl 3):S409-S412.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/20830523/pubmed" id="20830523" target="_blank">20830523</a>]</span>
<span class="doi">10.1007/s10545-010-9202-7</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27838199">
<a name="27838199"></a>Burnes ML, Boettcher BT, Woehlck HJ, et al. Hydroxocobalamin as a Rescue Treatment for Refractory Vasoplegic Syndrome After Prolonged Cardiopulmonary Bypass. <i>J Cardiothor Vasc Anesth.</i> 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/27838199/pubmed" id="27838199" target="_blank">27838199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28994688">
<a name="28994688"></a>Cai Y, Mack A, Ladlie BL, Martin AK. The use of intravenous hydroxocobalamin as a rescue in methylene blue-resistant vasoplegic syndrome in cardiac surgery. <i>Ann Card Anaesth</i>. 2017;20(4):462-464. doi:10.4103/aca.ACA_88_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/28994688/pubmed" id="28994688" target="_blank">28994688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18606874">
<a name="18606874"></a>Carmel R. How I treat cobalamin (vitamin B12) deficiency. <i>Blood</i>. 2008;112(6):2214-2221. doi:10.1182/blood-2008-03-040253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/18606874/pubmed" id="18606874" target="_blank">18606874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8010551">
<a name="8010551"></a>Curry SC, Connor DA, Raschke RA. Effect of the Cyanide Antidote Hydroxocobalamin on Commonly Ordered Serum Chemistry Studies. <i>Ann Emerg Med</i>. 1994;24(1):65-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/8010551/pubmed" id="8010551" target="_blank">8010551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BTG.1">
<a name="BTG.1"></a>Cyanokit (hydroxocobalamin) [prescribing information]. West Conshohocken, PA: BTG International Inc; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19406507">
<a name="19406507"></a>Dart RC, Borron SW, Caravati EM, et al. Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care. <i>Ann Emerg Med</i>. 2009;54(3):386-394.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/19406507/pubmed" id="19406507" target="_blank">19406507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24942828">
<a name="24942828"></a>Devalia V, Hamilton MS, Molloy AM; British Committee for Standards in Haematology. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. <i>Br J Haematol</i>. 2014;166(4):496-513. doi:10.1111/bjh.12959<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/24942828/pubmed" id="24942828" target="_blank">24942828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28644688">
<a name="28644688"></a>Elliott A, Dubé PA, Cossette-Côté A, et al. Intraosseous administration of antidotes - a systematic review. <i>Clin Toxicol (Phila)</i>. 2017;55(10):1025-1054. doi:10.1080/15563650.2017.1337122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/28644688/pubmed" id="28644688" target="_blank">28644688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21396232">
<a name="21396232"></a>Fujita Y, Fujino Y, Onodera M, et al. A fatal case of acute hydrogen sulfide poisoning caused by hydrogen sulfide: hydroxocobalamin therapy for acute hydrogen sulfide poisoning. <i>J Anal Toxicol</i>. 2011;35(2):119-123. doi:10.1093/anatox/35.2.119<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/21396232/pubmed" id="21396232" target="_blank">21396232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21530137">
<a name="21530137"></a>Geraci MJ, McCoy SL, and Aquino ME, "Woman With Red Urine: Hydroxocobalamin-Induced Chromaturia," <i>J Emerg Med</i>, 2012, 43(3):e207-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/21530137/pubmed" id="21530137" target="_blank">21530137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25953825">
<a name="25953825"></a>Goraya JS, Kaur S, Mehra B. Neurology of nutritional vitamin B12 deficiency in infants: case series from India and literature review. <i>J Child Neurol</i>. 2015;30(13):1831-1837.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/25953825/pubmed" id="25953825" target="_blank">25953825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15628833">
<a name="15628833"></a>Gracia R and Shepherd G, "Cyanide Poisoning and Its Treatment," <i>Pharmacotherapy</i>, 2004, 24(10):1358-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/15628833/pubmed" id="15628833" target="_blank">15628833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17098327">
<a name="17098327"></a>Hall AH, Dart R, and Bogdan G, “Sodium Thiosulfate or Hydroxocobalamin For The Empiric Treatment of Cyanide Poisoning?” <i>Ann Emerg Med</i>, 2007, 49(6):806-813.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/17098327/pubmed" id="17098327" target="_blank">17098327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25546714">
<a name="25546714"></a>Haouzi P, Chenuel B, Sonobe T. High-dose hydroxocobalamin administered after H2S exposure counteracts sulfide-poisoning-induced cardiac depression in sheep. <i>Clin Toxicol (Phila)</i>. 2015;53(1):28-36. doi:10.3109/15563650.2014.990976<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/25546714/pubmed" id="25546714" target="_blank">25546714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holstege.1">
<a name="Holstege.1"></a>Holstege CP, Kirk MA. Cyanide and hydrogen sulfide. Chapter 123. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds. New York, NY: McGraw-Hill; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27905001">
<a name="27905001"></a>Huemer M, Diodato D, Schwahn B, et al. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. <i>J Inherit Metab Dis</i>. 2017;40(1):21-48. doi:10.1007/s10545-016-9991-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/27905001/pubmed" id="27905001" target="_blank">27905001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16227032">
<a name="16227032"></a>Huemer M, Simma B, Fowler B, Suormala T, Bodamer OA, Sass JO. Prenatal and postnatal treatment in cobalamin C defect. <i>J Pediatr</i>. 2005;147(4):469-472. doi:10.1016/j.jpeds.2005.04.040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/16227032/pubmed" id="16227032" target="_blank">16227032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Actavis.1">
<a name="Actavis.1"></a>Hydroxocobalamin injection [prescribing information]. Parsippany, NJ: Actavis Pharma, Inc.; January 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>IOM (Institute of Medicine), Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin and Choline, Washington, DC: National Academy Press, 1998.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28969436">
<a name="28969436"></a>Jiwani AZ, Bebarta VS, Cancio LC. Acquired methemoglobinemia after hydroxocobalamin administration in a patient with burns and inhalation injury. <i>Clin Toxicol</i>. 2018;56(5):370-372.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/28969436/pubmed" id="28969436" target="_blank">28969436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11972107">
<a name="11972107"></a>Kind T, Levy J, Lee M, Kaicker S, Nicholson JF, Kane SA. Cobalamin C disease presenting as hemolytic-uremic syndrome in the neonatal period. <i>J Pediatr Hematol Oncol</i>. 2002;24(4):327-329. doi:10.1097/00043426-200205000-00023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/11972107/pubmed" id="11972107" target="_blank">11972107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12086562">
<a name="12086562"></a>Lane LA, Rojas-Fernandez C. Treatment of vitamin b(12)-deficiency anemia: oral versus parenteral therapy. <i>Ann Pharmacother</i>. 2002;36(7-8):1268-1272.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/12086562/pubmed" id="12086562" target="_blank">12086562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28925645">
<a name="28925645"></a>Langan RC, Goodbred AJ. Vitamin B12 deficiency: recognition and management. <i>Am Fam Physician</i>. 2017;96(6):384-389.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/28925645/pubmed" id="28925645" target="_blank">28925645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26891675">
<a name="26891675"></a>Legrand M, Michel T, Daudon M, et al. Risk of oxalate nephropathy with the use of cyanide antidote hydroxocobalamin in critically ill burn patients. <i>Intensive Care Med</i>. 2016;42(6):1080-1081.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/26891675/pubmed" id="26891675" target="_blank">26891675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3374544">
<a name="3374544"></a>Lindenbaum J, Healton EB, Savage DG, et al, “Neuropsychiatric Disorders Caused by Cobalamin Deficiency in the Absence of Anemia or Macrocytosis,” <i>N Engl J Med</i>, 1988, 318(26):1720-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/3374544/pubmed" id="3374544" target="_blank">3374544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33692053">
<a name="33692053"></a>Mastenbrook J, Zamihovsky R, Brunken N, Olsen T. Intraosseous administration of hydroxocobalamin after enclosed structure fire cardiac arrest. <i>BMJ Case Rep</i>. 2021;14(3):e239523. doi:10.1136/bcr-2020-239523<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/33692053/pubmed" id="33692053" target="_blank">33692053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Means.2021">
<a name="Means.2021"></a>Means RT, Fairfield KM. Treatment of vitamin B12 and folate deficiencies. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 27, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24196100">
<a name="24196100"></a>Mintegi S, Clerigue N, Tipo V, et al. Pediatric cyanide poisoning by fire smoke inhalation: a European expert consensus. Toxicology Surveillance System of the Intoxications Working Group of the Spanish Society of Paediatric Emergencies. <i>Pediatr Emerg Care</i>. 2013;29(11):1234-1240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/24196100/pubmed" id="24196100" target="_blank">24196100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.2021">
<a name="NIH.2021"></a>National Institutes of Health (NIH). Vitamin B12 - health professional. <a href="https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/" target="_blank">https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/</a>. Updated April 6, 2021. Accessed August 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27554631">
<a name="27554631"></a>Nguyen L, Afshari A, Kahn SA, McGrane S, Summitt B. Utility and outcomes of hydroxocobalamin use in smoke inhalation patients. <i>Burns</i>. 2017;43(1):107-113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/27554631/pubmed" id="27554631" target="_blank">27554631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2930611">
<a name="2930611"></a>Olszewski AJ, Szostak WB, Bialkowska M, et al. Reduction of Plasma Lipid and Homocysteine Levels by Pyridoxine, Folate, Cobalamin, Choline, Riboflavin, and Troxerutin in Atherosclerosis. <i>Atherosclerosis</i>. 1989;75(1):1-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/2930611/pubmed" id="2930611" target="_blank">2930611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Orkin.1">
<a name="Orkin.1"></a>Orkin S, Nathan D, Ginsbirg, D, et al, eds. <i>Nathan and Oski's Hematology and Oncology of Infancy and Childhood</i>. 8th ed. Saunders Elsevier; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30598380">
<a name="30598380"></a>Ortoleva JP, Cobey FC. A systematic approach to the treatment of vasoplegia based on recent advances in pharmacotherapy. <i>J Cardiothorac Vasc Anesth</i>. 2019;33(5):1310-1314. doi:10.1053/j.jvca.2018.11.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/30598380/pubmed" id="30598380" target="_blank">30598380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28392254">
<a name="28392254"></a>Parrott J, Frank L, Rabena R, Craggs-Dino L, Isom KA, Greiman L. American Society for Metabolic and Bariatric Surgery integrated health nutritional guidelines for the surgical weight loss patient 2016 update: micronutrients. <i>Surg Obes Relat Dis</i>. 2017;13(5):727-741. doi:10.1016/j.soard.2016.12.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/28392254/pubmed" id="28392254" target="_blank">28392254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Powers.1">
<a name="Powers.1"></a>Powers JM. Nutritional anemias. In: Fish JD, Lipton JM, Lanzkowsky P, eds. <i>Lanzkowsky's Manual of Pediatric Hematology and Oncology</i>. 7th ed. Academic Press; 2021:chap. 4.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22672162">
<a name="22672162"></a>Reade MC, Davies SR, Morley PT, et al. Review Article: Management of Cyanide Poisoning. <i>Emerg Med Australas</i>. 2012;24(3):225-238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/22672162/pubmed" id="22672162" target="_blank">22672162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1627675">
<a name="1627675"></a>Regland B, Gottfries CG, Lindstedt G. Dementia Patients With Low Serum Cobalamin Concentration: Relationship to Atrophic Gastritis. <i>Aging (Milano)</i>. 1992;4(1):35-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/1627675/pubmed" id="1627675" target="_blank">1627675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22293595">
<a name="22293595"></a>Roderique EJ, Gebre-Giorgis AA, Stewart DH, Feldman MJ, Pozez AL. Smoke inhalation injury in a pregnant patient: a literature review of the evidence and current best practices in the setting of a classic case. <i>J Burn Care Res</i>. 2012;33(5):624-633.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/22293595/pubmed" id="22293595" target="_blank">22293595</a>]</span>
<span class="doi">10.1097/BCR.0b013e31824799d2</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24792267">
<a name="24792267"></a>Roderique JD, VanDyck K, Holman B, et al. The use of high-dose hydroxocobalamin for vasoplegic syndrome. <i>Ann Thor Surg</i>. 2014;97(5):1785-1786.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/24792267/pubmed" id="24792267" target="_blank">24792267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22711730">
<a name="22711730"></a>Roumeliotis N, Dix D, Lipson A. Vitamin B(12) deficiency in infants secondary to maternal causes. <i>CMAJ</i>. 2012;184(14):1593-1598.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/22711730/pubmed" id="22711730" target="_blank">22711730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sachdev.1">
<a name="Sachdev.1"></a>Sachdev HPS, Shah D. Vitamin B complex deficiencies and excess. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 62.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11385334">
<a name="11385334"></a>Sauer SW, Keim ME. Hydroxocobalamin: Improved Public Health Readiness for Cyanide Disasters. <i>Ann Emerg Med</i>. 2001;37(6):635-641.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/11385334/pubmed" id="11385334" target="_blank">11385334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29209927">
<a name="29209927"></a>Shah PR, Reynolds PS, Pal N, Tang D, McCarthy H, Spiess BD. Hydroxocobalamin for the treatment of cardiac surgery-associated vasoplegia: a case series. <i>Can J Anaesth</i>. 2018;65(5):560-568. doi:10.1007/s12630-017-1029-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/29209927/pubmed" id="29209927" target="_blank">29209927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30217583">
<a name="30217583"></a>Shapeton AD, Mahmood F, Ortoleva JP. Hydroxocobalamin for the treatment of vasoplegia: a review of current literature and considerations for use. <i>J Cardiothorac Vasc Anesth</i>. 2019;33(4):894-901. doi:10.1053/j.jvca.2018.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/30217583/pubmed" id="30217583" target="_blank">30217583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18397973">
<a name="18397973"></a>Shepherd G, Velez LI. Role of Hydroxocobalamin in Acute Cyanide Poisoning. <i>Ann Pharmacother</i>. 2008;42(5):661-669.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/18397973/pubmed" id="18397973" target="_blank">18397973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3604755">
<a name="3604755"></a>Skouby AP. Hydroxocobalamin for initial and long-term therapy for vitamin B12 deficiency. <i>Acta Med Scand</i>. 1987;221(4):399-402.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/3604755/pubmed" id="3604755" target="_blank">3604755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23301732">
<a name="23301732"></a>Stabler SP. Clinical practice. Vitamin B12 deficiency. <i>N Engl J Med</i>. 2013;368(2):149-160. doi:10.1056/NEJMcp1113996<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/23301732/pubmed" id="23301732" target="_blank">23301732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23163594">
<a name="23163594"></a>Thompson JP, Marrs TC. Hydroxocobalamin in Cyanide Poisoning. <i>Clin Toxicol</i>. 2012;50(10):875-885.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/23163594/pubmed" id="23163594" target="_blank">23163594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26678525">
<a name="26678525"></a>Torsvik IK, Ueland PM, Markestad T, Midttun Ø, Bjørke Monsen AL. Motor development related to duration of exclusive breastfeeding, B vitamin status and B12 supplementation in infants with a birth weight between 2000-3000 g, results from a randomized intervention trial. <i>BMC Pediatr</i>. 2015;15:218.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/26678525/pubmed" id="26678525" target="_blank">26678525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24305960">
<a name="24305960"></a>Trakadis YJ, Alfares A, Bodamer OA, et al. Update on transcobalamin deficiency: clinical presentation, treatment and outcome. <i>J Inherit Metab Dis</i>. 2014;37(3):461-473. doi:10.1007/s10545-013-9664-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/24305960/pubmed" id="24305960" target="_blank">24305960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17976885">
<a name="17976885"></a>Truong DH, Mihajlovic A, Gunness P, Hindmarsh W, O'Brien PJ. Prevention of hydrogen sulfide (H2S)-induced mouse lethality and cytotoxicity by hydroxocobalamin (vitamin B(12a)). <i>Toxicology</i>. 2007;242(1-3):16-22. doi:10.1016/j.tox.2007.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/17976885/pubmed" id="17976885" target="_blank">17976885</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27749291">
<a name="27749291"></a>Woehlck HJ, Boettcher BT, Lauer KK, et al. Hydroxocobalamin for vasoplegic syndrome in liver transplantation: restoration of blood pressure without vasospasm.<i> A A Case Rep</i>. 2016;7(12):247-250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/27749291/pubmed" id="27749291" target="_blank">27749291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27338592">
<a name="27338592"></a>Wong SL, Pudek M, Li D. Wine-Colored Plasma and Urine from Hydroxocobalamin Treatment. <i>J Gen Intern Med.</i> 2016;32(2):225-226.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/27338592/pubmed" id="27338592" target="_blank">27338592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/.</div>
</li></ol></div><div id="topicVersionRevision">Topic 13365 Version 171.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
